SOMERSET, NJ, September 17, 2013 – Catalent Pharma Solutions, a leading global drug delivery technology and advanced supply solutions company, and Supernus Pharmaceuticals, a specialty pharmaceuticals company, have entered into an agreement where Catalent is the supplier of Trokendi XRTM extended release capsules for Supernus.
Supernus developed Trokendi XR using its own advanced drug delivery technology and transferred its formulation to Catalent for commercial manufacturing.
“Supernus selected Catalent as our commercial supply partner based on their extensive experience in manufacturing extended release products, the longstanding relationship we have had with them, and a proven track record of high quality.” said Jack Khattar, Chief Executive Officer, President and Director of Supernus.
Barry Littlejohns, President of Catalent’s Advanced Delivery Technologies business, said “We offer customers integrated solutions that include both proprietary drug delivery technologies and advanced supply solutions for oral controlled release development and commercial products. We are pleased to have been selected by Supernus to work on this unique epilepsy product.”
Trokendi XR is a novel, oral, extended-release, once-daily formulation of topiramate for the treatment of epilepsy. Supernus recently received approval from the FDA and launched the product in the US market. Trokendi XR delivers an extended-release form of topiramate, one of the most effective anti epilepsy drugs.
Trokendi XR is a convenient once per day alternative to current immediate release formulation products which require patients to administer their medication multiple times per day.
To learn more about Catalent’s modified release technologies, please visit http://www.catalent.com/index.php#delivery.
About Catalent
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™
Trokendi XR and Oxtellar XR are trademarks of Supernus Pharmaceuticals, Inc.